Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTONIO adjuvant atezolizumab in MSI-high/dMMR colorectal cancer
2020-002715-21Phase 2Active
- Sponsor
- AIO-Studien
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in colorectal cancer (CRC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Disease-free survival rate at 3 years. Started Feb 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-002715-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002715-21.